Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid in infants with severe osteogenesis imperfecta
ISRCTN95879580Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2009
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of zoledronic acid in osteogenesis imperfecta (OI), sponsored by Novartis. Primary endpoint: Change in lumbar spine bone mineral density Z-score at month 24. Started Oct 2009; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on ISRCTN95879580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN95879580.